+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Cerebral Palsy (CP) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • PDF Icon


  • 40 Pages
  • February 2019
  • Region: Global
  • VPA Research
  • ID: 4749278
The global demand for Cerebral Palsy (CP) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cerebral Palsy (CP) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cerebral Palsy (CP) pipeline companies from advancing their products into Phase 3 or Phase 4.

Cerebral Palsy (CP) Report Description

The 2019 pipeline study on Cerebral Palsy (CP) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cerebral Palsy (CP) pipeline compounds.

The Cerebral Palsy (CP) pipeline guide presents information on all active drugs currently being developed for Cerebral Palsy (CP). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Cerebral Palsy (CP) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cerebral Palsy (CP) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Cerebral Palsy (CP) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Cerebral Palsy (CP) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Cerebral Palsy (CP) pipeline report includes
  • An overview of Cerebral Palsy (CP) disease including symptoms, causes, diagnosis and available treatment options is provided.

  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

  • Phase wise count of Cerebral Palsy (CP) pipeline

  • Company wise list of Cerebral Palsy (CP) pipeline

  • Mechanism of Action wise Cerebral Palsy (CP) pipeline

For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

  • Current status of development

  • Drug overview

  • Mechanism of Action

  • Pre-clinical and Clinical Trials/Results

  • Company Overview and Recent Developments

Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations

  • Get clear understanding of the entire Cerebral Palsy (CP) pipeline, with details on active projects

  • Stay ahead of the competition through comprehensive knowledge of Cerebral Palsy (CP) pipeline progress

  • Get in detail information of each product with updated information on each project along with key milestones

  • Gain clear insights into companies participating in Cerebral Palsy (CP) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

  • Get trial information for each pipeline product under development

  • Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Table of Contents

1.1 List of Tables

1.2 List of Figures

2. Global Cerebral Palsy (CP) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Cerebral Palsy (CP) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Cerebral Palsy (CP) pipeline, H1- 2019
3.5 Mechanism of Action wise Cerebral Palsy (CP) Pipeline Candidates

4 CHA Bio & Diostech Co Ltd Cerebral Palsy (CP) Pipeline Details
4.1 CHA Bio & Diostech Co Ltd Business Profile
4.2 CHA Bio & Diostech Co Ltd Cerebral Palsy (CP) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 CytoDel LLC Cerebral Palsy (CP) Pipeline Details
5.1 CytoDel LLC Business Profile
5.2 CytoDel LLC Cerebral Palsy (CP) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 GW Pharmaceuticals Plc Cerebral Palsy (CP) Pipeline Details
6.1 GW Pharmaceuticals Plc Business Profile
6.2 GW Pharmaceuticals Plc Cerebral Palsy (CP) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Hugel Inc Cerebral Palsy (CP) Pipeline Details
7.1 Hugel Inc Business Profile
7.2 Hugel Inc Cerebral Palsy (CP) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Medy-Tox Inc Cerebral Palsy (CP) Pipeline Details
8.1 Medy-Tox Inc Business Profile
8.2 Medy-Tox Inc Cerebral Palsy (CP) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Meridigen Biotech Co Ltd Cerebral Palsy (CP) Pipeline Details
9.1 Meridigen Biotech Co Ltd Business Profile
9.2 Meridigen Biotech Co Ltd Cerebral Palsy (CP) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Latest Cerebral Palsy (CP) Drug Pipeline Developments, 2019

11. Appendix
11.1 About Us
11.2 Sources and Methodology
11.3 Contact Information

Companies Mentioned

  • CHA Bio & Diostech Co Ltd

  • CytoDel LLC

  • GW Pharmaceuticals Plc

  • Hugel Inc

  • Medy-Tox Inc

  • Meridigen Biotech Co Ltd